India’s Lupin Says Ready To Present Mandideep Plan To U.S. FDA; Push On Novel Drug Delivery, Biosimilars And Indian Market To Propel Revenue Growth
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Indian drug maker Lupin hopes to clear up issues with U.S. regulators on its Mandideep-based manufacturing unit, which has been issued warning letters by the U.S. FDA. The FDA had charged the facility deviated from current good manufacturing practices in the production of oral and injectable cephalosporins in November 2008
You may also be interested in...
Ranbaxy Transfers Atorvastatin, Tamsulosin Filings To Ohm Labs While Valacyclovir Rakes Big Gains
MUMBAI - Ranbaxy - the Indian affiliate of Daiichi Sankyo - is believed to have transferred its abbreviated new drug application filing for Lipitor to its New Jersey-based Ohm Labs facility, after U.S. FDA imposed import restrictions last summer on two of its biggest manufactuirng facilities in India
Ranbaxy Transfers Atorvastatin, Tamsulosin Filings To Ohm Labs While Valacyclovir Rakes Big Gains
MUMBAI - Ranbaxy - the Indian affiliate of Daiichi Sankyo - is believed to have transferred its abbreviated new drug application filing for Lipitor to its New Jersey-based Ohm Labs facility, after U.S. FDA imposed import restrictions last summer on two of its biggest manufactuirng facilities in India
Ranbaxy Transfers Atorvastatin, Tamsulosin Filings To U.S. Ohm Labs After FDA Crackdown
Billings for valacyclovir, generic Valtrex, which Ranbaxy shifted earlier to its New Jersey affiliate, reached $100 million within the first week of the U.S. launch.